Low Density Lipoprotein (LDL) News and Research

RSS

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Being mildly overweight benefits ALS patients

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts General Hospital researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

12 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

Scleroderma is an independent determinant for coronary calcification, study suggests

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis.

11 May 2011

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis. Conventional cardiovascular risk factors such as age and hypertension predispose patients with systemic sclerosis to plaque build-up in the heart arteries similar to the general population. Details of this study are now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

10 May 2011

'Bad cholesterol' needed to gain more muscle mass

The so-called "bad cholesterol" - low-density lipoprotein commonly called LDL - may not be so bad after all, shows a Texas A&M University study that casts new light on the cholesterol debate, particularly among adults who exercise.

6 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

Interval training and healthy eating are perfect solutions for obesity sufferers

A program which combines interval training and healthy eating practices seems to be perfectly indicated for those suffering from obesity, according to the results of a new study from the Montreal Hearth Institute's centre for preventive medicine and physical activity.

29 Apr 2011

Melatonin can help fight obesity and risks associated with it

University of Granada researchers have proven that melatonin -a natural hormone produced by the body- helps in controlling weight gain -even without reducing the intake of food-, improves blood lipid profile -as it reduces triglicerids-, increases HDL cholesterol and reduces LDL cholesterol.

29 Apr 2011

Diabetes and prediabetes are on the rise: New medication in research trials

As the newest statistics from the CDC show, diabetes is an ever increasing problem for Americans. Almost 26 million adults in this country now have diabetes, an increase of 9% since 2008. Ninety to 95% of cases are type 2 diabetes, marked by a gradual inability of the body’s cells to respond to insulin, and eventually an inability to produce enough insulin. In addition, almost 79 million people in this country have prediabetes. The CDC has warned that if diabetes continues on its current course, it could affect a third of all adult Americans by 2050.

26 Apr 2011

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Many genes that cause human diseases have parallel genes in other organisms, including yeast. Now Columbia University researchers have used an innovative yeast-based screening method to identify a possible treatment for the fatal childhood disease Niemann-Pick C.

19 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.

11 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

Two new studies on Veterans Affairs health care system

As recently as the 1990s, the Veterans Affairs health care system had a subpar reputation for quality, but two new studies of standard quality metrics, both led by Amal Trivedi, assistant professor of community health at Brown University and a physician at the Providence VA Medical Center, show that the system that cares for more than 5 million patients has improved markedly in the last decade.

8 Apr 2011

Computational modeling provides more knowledge of lipoprotein properties

Computational modeling increases our knowledge of lipoprotein properties that cannot be measured using experimental methods. Lipoproteins are particles that transport cholesterol in our bloodstream. According to the doctoral dissertation of Master of Science in Technology Linda Kumpula (Aalto University School of Science), the differences in the composition, size and number of lipoprotein particles transporting cholesterol in individuals can be computationally modeled using experimental data.

8 Apr 2011

ASBMB to honor 11 scientists with annual awards for biomedical research

The winners of the American Society for Biochemistry and Molecular Biology annual awards will give lectures at the Experimental Biology 2011 conference April 9-13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance (NMR) technology, today announced presentations of two clinical studies "from the podium" at the 60th Annual Scientific Session of the American College of Cardiology.

6 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Low Density Lipoprotein (LDL) News and Research

Medical food resolves metabolic syndrome and cardiovascular risk factors

Being mildly overweight benefits ALS patients

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Scleroderma is an independent determinant for coronary calcification, study suggests

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

'Bad cholesterol' needed to gain more muscle mass

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Interval training and healthy eating are perfect solutions for obesity sufferers

Melatonin can help fight obesity and risks associated with it

Diabetes and prediabetes are on the rise: New medication in research trials

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

Investigational drug effective for patients with obesity

Two new studies on Veterans Affairs health care system

Computational modeling provides more knowledge of lipoprotein properties

ASBMB to honor 11 scientists with annual awards for biomedical research

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

TZDs might serve as new agents for addiction treatment

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News